Login to Your Account



InterMune Tweaks Design for Confirmatory Esbriet IPF Study

By Jennifer Boggs


Friday, May 27, 2011
Executives of Brisbane, Calif.-based InterMune Inc. disclosed details for the upcoming confirmatory trial needed for U.S. approval of idiopathic pulmonary fibrosis (IPF) drug Esbriet (pirfenidone) and told analysts Thursday that they believe some fine-tuning to the trial design could help the drug finally clear the FDA.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription